BridgeBio Pharma (BBIO) Receivables (2021 - 2026)

BridgeBio Pharma's Receivables history runs 5 years deep, the most recent figure standing at $205.2 million for Q1 2026.

• In Q1 2026, Receivables rose 78.05% year-over-year to $205.2 million; the TTM figure through Mar 2026 stood at $205.2 million (up 78.05% YoY), while the FY2025 annual figure was $139.4 million, up 2853.07% from the prior year.
• Receivables came in at $205.2 million for Q1 2026 at BridgeBio Pharma, up from $139.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $205.2 million in Q1 2026 to a low of $2.4 million in Q4 2023.
• A 4-year average of $94.3 million and a median of $115.3 million in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 2853.07% in 2025 and surged 78.05% in 2026, its largest moves.
• BridgeBio Pharma's Receivables stood at $2.4 million in 2023, then jumped by 100.85% to $4.7 million in 2024, then soared by 2853.07% to $139.4 million in 2025, then soared by 47.17% to $205.2 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $205.2 million, $139.4 million, and $116.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison